| Market Cap | 28.14K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -3.82M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | - |
| Sales | 359.46k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -90.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -99.00% |
| Recommedations | - | Quick Ratio | 0.03 | Shares Outstanding | 93.81M | 52W Low Chg | 50.00% |
| Insider Own | 23.54% | ROA | -308.10% | Shares Float | 36.59M | Beta | 1.65 |
| Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.00030 |
| Gross Margin | -51.03% | Profit Margin | - | Avg. Volume | 1,765 | Target Price | - |
| Oper. Margin | -618.48% | Earnings Date | - | Volume | 10,000 | Change | 0.00% |
Neuropathix, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics from its proprietary synthetic cannabinoid derivatives platform. It engages in the research and development of chemical entities, such as KLS-13019, KLS-13023, and KLS-13022, as well as its related molecules; and synthetic cannabidiol therapeutics through pre-clinical drug discovery and development processes for use in the disease indications of chemotherapy induced peripheral neuropathy, overt hepatic encephalopathy, mild traumatic brain injury, and chronic traumatic encephalopathy. The company was formerly known as Kannalife, Inc. and changed its name to Neuropathix, Inc. in November 2020. Neuropathix, Inc. was founded in 2010 and is based in Doylestown, Pennsylvania.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| PETKANAS DEAN | Chief Executive Offi.. Chief Executive Officer | Jan 05 | Sell | 0.02 | 320,000 | 6,400 | 23,559,029 | 06/13/22 |